| 词条 | Blosozumab |
| 释义 |
| Verifiedfields = changed | Watchedfields = changed | verifiedrevid = 457463532 | type = mab | image = | alt = | mab_type = mab | source = zu/o | target = SOST | tradename = | Drugs.com = | MedlinePlus = | pregnancy_AU = | pregnancy_US = | pregnancy_category= | legal_AU = | legal_CA = | legal_UK = | legal_US = | legal_status = | routes_of_administration = | bioavailability = | protein_bound = | metabolism = | elimination_half-life = | excretion = | CAS_number_Ref = {{cascite|changed|??}} | CAS_number = 1132758-87-2 | ATC_prefix = none | ATC_suffix = | PubChem = | DrugBank_Ref = {{drugbankcite|correct|drugbank}} | DrugBank = | ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}} | ChemSpiderID = none | KEGG = D10094 | KEGG_Ref = {{keggcite|changed|kegg}} | C=6462 | H=9852 | N=1684 | O=2030 | S=46 | molecular_weight = 144.63 kg/mol }}Blosozumab binds SOST, a negative regulator of osteoblast activity. Blocking SOST activity can lead to increased bone density.[1] Blosozaumab has been studied with regards to the treatment of osteoporosis in both men and postmenopausal women. Clinical trials with Blosozumab have shown the antibody to be well tolerated and effective in producing a bone anabolic effect.[2] Blosozumab was developed by Eli Lilly and Company. References1. ^{{cite journal | author = World Health Organization | title = International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 105 | journal = WHO Drug Information | volume = 25 | issue = 2 | year = 2011 | url = http://www.who.int/medicines/publications/druginformation/innlists/Final_PL105.pdf | format = PDF }}{{dead link|date=July 2017 |bot=InternetArchiveBot |fix-attempted=yes }} {{Monoclonals for bone, musculoskeletal, circulatory, and neurologic systems}}{{monoclonal-antibody-stub}}{{musculoskeletal-drug-stub}}2. ^{{Cite journal|last=McColm|first=Juliet|last2=Hu|first2=Leijun|last3=Womack|first3=Theresa|last4=Tang|first4=Cheng Cai|last5=Chiang|first5=Alan Y|date=2014-04-01|title=Single- and Multiple-Dose Randomized Studies of Blosozumab, a Monoclonal Antibody Against Sclerostin, in Healthy Postmenopausal Women|journal=Journal of Bone and Mineral Research|language=en|volume=29|issue=4|pages=935–943|doi=10.1002/jbmr.2092|pmid=23996473|issn=1523-4681}} 1 : Eli Lilly and Company |
| 随便看 |
|
开放百科全书收录14589846条英语、德语、日语等多语种百科知识，基本涵盖了大多数领域的百科知识，是一部内容自由、开放的电子版国际百科全书。